Sun Pharmaceutical Industries has reported results for third quarter ended December 31, 2016.
The company has reported a net loss of Rs 162.66 crore for the quarter ended December 31, 2016 as compared to a net loss of Rs 142.27 crore for the same quarter in the previous year. However, total income of the company increased by 4.38% at Rs 2012.81 crore for the quarter under review as compared Rs 1928.39 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 4.73% fall in its net profit after taxes, non-controlling interest and share of profit of associates & joint ventures at Rs 1471.82 crore for the quarter ended December 31, 2016, as compared to Rs 1544.85 crore for the same quarter in the previous year. However, total income of the company increased by 10.14% at Rs 8034.81 crore for the quarter under review as compared Rs 7295.20 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: